Spyre Therapeutics, Inc.
SYREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Spyre Therapeutics, Inc. (SYRE) is listed under Biotechnology. The company carries a $8.44B market cap, placing it firmly in the mid-cap category. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Market Cap
$8.44B
Beta
3.11
P/E (TTM)
—
P/E (Fwd)
-25.77
EPS (TTM)
$-1.92
EPS (Fwd)
$-3.51
ROE
-23.0%
ROA
-19.8%
Cash
$1.15B
Total Debt
$0
Free CF
-$89.1M
52W Change
267.6%
Annual Financials
Cash vs Debt
Where SYRE stands vs its 150-day and 200-day moving averages
As of the October 14, 2026 close, SYRE finished 0.31% below its 150-day moving average ($80.70) and 15.94% above its 200-day moving average ($69.39). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SYRE overbought or oversold?
At the October 14, 2026 close, SYRE's RSI(14) was 39.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Spyre Therapeutics, Inc. reports $1.15B in cash and $0 in total debt. The company is burning cash, with free cash flow at -$89.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -23.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $2.3M (2022) to $0 (2025), a 100% decline worth watching.
With a beta above 1.5, SYRE tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SYRE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.